Eli Lilly Is Getting Into the Hearing Loss Market in a $1.12 Billion Deal With Seamless Therapeutics
Much of Eli Lilly's (NYSE: LLY) recent popularity as a stock is due to its obesity drug Zepbound. While it's understandable that investors are excited about how quickly and effectively the company has become a powerhouse in the hot weight loss segment, it's also quietly building its presence in another high-potential healthcare niche. This is genetic medicine, which harnesses technology that uses the body's DNA to diagnose and treat health issues.It was announced recently that Lilly had entered into a collaboration and licensing deal with biotech Seamless Therapeutics to develop medicines targeting hearing loss disorders. Let's take a brief look at this deal and determine whether it can be beneficial for Lilly stock. Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool
Übrigens: Eli Lilly und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und Neukunden-Bonus sichern!
Ausgewählte Hebelprodukte auf Eli Lilly
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Eli Lilly
Der Hebel muss zwischen 2 und 20 liegen
| Name | Hebel | KO | Emittent |
|---|
| Name | Hebel | KO | Emittent |
|---|
Quelle: MotleyFool
